25,369 Shares in IQVIA Holdings Inc. $IQV Bought by Pinnbrook Capital Management LP

Pinnbrook Capital Management LP bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the third quarter, Holdings Channel reports. The fund bought 25,369 shares of the medical research company’s stock, valued at approximately $4,819,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its holdings in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares during the period. Empowered Funds LLC grew its holdings in shares of IQVIA by 102.1% during the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares during the period. Sivia Capital Partners LLC purchased a new stake in shares of IQVIA during the 2nd quarter worth about $514,000. Penserra Capital Management LLC increased its position in IQVIA by 10.3% during the 2nd quarter. Penserra Capital Management LLC now owns 963 shares of the medical research company’s stock worth $151,000 after purchasing an additional 90 shares in the last quarter. Finally, ProShare Advisors LLC raised its holdings in IQVIA by 6.8% in the second quarter. ProShare Advisors LLC now owns 34,139 shares of the medical research company’s stock valued at $5,380,000 after buying an additional 2,170 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Up 1.1%

IQV opened at $164.78 on Friday. The firm’s 50 day moving average is $201.58 and its 200-day moving average is $206.67. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The firm has a market capitalization of $27.96 billion, a P/E ratio of 20.96, a P/E/G ratio of 1.57 and a beta of 1.39.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on IQV. Truist Financial decreased their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Jefferies Financial Group cut their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. UBS Group decreased their price target on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. cut their price objective on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has an average rating of “Buy” and an average target price of $229.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.